Wells Fargo lowered the firm’s price target on Ironwood to $14 from $20 and keeps an Overweight rating on the shares. The firm thinks Ironwood has a drug on hand and differentiation could come from the sales effort and weekly dosing, but the lack of other clinical differentiation brings down peak sales to $500M, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IRWD:
- Ironwood reports ‘positive’ results from Phase III trial of apraglutide
- Jefferies biotechnology analysts hold an analyst/industry conference call
- Ironwood price target raised to $21 from $20 at Piper Sandler
- Ironwood price target raised to $18 from $15 at Capital One
- Ironwood sees FY24 revenue $435M-$455M, consensus $462.82M